Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis
Pan Ma, Jing Liu, Juan Qin, et al.
Circulation (2023) Vol. 149, Iss. 1, pp. 48-66
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure
Tamás G. Gergely, Zsófia D. Drobni, Marinos Kallikourdis, et al.
Nature Reviews Cardiology (2024) Vol. 21, Iss. 7, pp. 443-462
Closed Access | Times Cited: 11
Type 1 diabetes, its complications, and non-ischemic cardiomyopathy: a mendelian randomization study of European ancestry
Yunyue Zhao, Enxi Quan, Tao Zeng, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Autoimmune Myocarditis, Old Dogs and New Tricks
Taejoon Won, E Song, Hannah M. Kalinoski, et al.
Circulation Research (2024) Vol. 134, Iss. 12, pp. 1767-1790
Open Access | Times Cited: 8
Interferons and interferon-related pathways in heart disease
Duc Tin Tran, Sri Nagarjun Batchu, Andrew Advani
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 7
Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors
Tamás G. Gergely, Zsófia D. Drobni, Nabil V. Sayour, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 6
Functional diversity of cardiac macrophages in health and disease
Steven Yang, Vinay Penna, Kory J. Lavine
Nature Reviews Cardiology (2025)
Closed Access
Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study
Yanxin Chen, Yuxi Luo, Yunwei Liu, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 2
Open Access
Advancing Myocarditis Research: Evaluating Animal Models for Enhanced Pathophysiological Insights
Yanzhe Xu, Y. H. Tan, Z. Y. Peng, et al.
Current Cardiology Reports (2025) Vol. 27, Iss. 1
Closed Access
Targeting the NLRP3 inflammasome abrogates cardiotoxicity of immune checkpoint blockers
Lu Yang, Jiamin Gao, Yachen Hou, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010127-e010127
Open Access
Increased pro-SFTPB in HDL promotes the pro-inflammatory transition of HDL and represents a sign of poor prognosis in ARDS patients
Liu Yang, Zhuo Xu, Zhenyan Wang, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Immune checkpoint inhibitors mediate myocarditis by promoting macrophage polarization via cGAS/STING pathway
Zhenzhu Cao, Yuxin Zhang, Huihui Jia, et al.
Cytokine (2025) Vol. 187, pp. 156873-156873
Closed Access
Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis
Yuhsin Vivian Huang, Yin Sun, Harrison Chou, et al.
Circulation Research (2025)
Closed Access
Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies
Xuwen Lin, Mei Xie, Jie Yao, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 3
Open Access | Times Cited: 4
Exploring T Cell Receptor Repertoires in Myocardial Diseases
DiyaaElDin Ashour, Kenz Le Gouge, Peter P. Rainer, et al.
Circulation Research (2024) Vol. 134, Iss. 12, pp. 1808-1823
Closed Access | Times Cited: 4
PANoptosis: a novel target for cardiovascular diseases
Q. Xiang, Zhen-Xi Geng, Xin Yi, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 8, pp. 739-756
Closed Access | Times Cited: 4
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity
Ying Wang, Carolin Ertl, Christina Schmitt, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 3
Anti‐CTLA‐4 m2a Antibody Exacerbates Cardiac Injury in Experimental Autoimmune Myocarditis Mice By Promoting Ccl5‐Neutrophil Infiltration
Ming‐Ming Wu, Yan‐Chao Yang, Yong‐Xu Cai, et al.
Advanced Science (2024)
Open Access | Times Cited: 3
Linking immune modulation to cardiac fibrosis
Frank M. Bengel, Jonathan A. Epstein, Robert J. Gropler, et al.
Nature Cardiovascular Research (2024) Vol. 3, Iss. 4, pp. 414-419
Closed Access | Times Cited: 3
Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities
Judith L. McKenzie, E. Sneath, Andrew Trinh, et al.
Immuno-Oncology Technology (2024) Vol. 21, pp. 100704-100704
Open Access | Times Cited: 2
MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy
Rosalyn M. Fey, Rebecca A. Nichols, Thuy Tran, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1773-1773
Open Access | Times Cited: 2
Molecular pathways and cellular subsets associated with adverse clinical outcomes in overlapping immune-related myocarditis and myositis
Bilal A. Siddiqui, Nicolas L. Palaskas, Sreyashi Basu, et al.
Cancer Immunology Research (2024) Vol. 12, Iss. 8, pp. 964-987
Open Access | Times Cited: 2
Intersection of Immunology and Metabolism in Myocardial Disease
Edward B. Thorp, Anja Karlstaedt
Circulation Research (2024) Vol. 134, Iss. 12, pp. 1824-1840
Closed Access | Times Cited: 2
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart
Amir Munir, Alan Gutierrez, Juan Qin, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 8, pp. 540-553
Closed Access | Times Cited: 2
Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation
Si-Jia Sun, Xiao‐Dong Jiao, Zhigang Chen, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab
Ludimila Cavalcante, Sreenivasa R Chandana, Nehal J. Lakhani, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 8, pp. e009475-e009475
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top